Senseonics Holdings announced that its Eversense 365 implantable continuous glucose monitor is now fully available in the United States when paired with Sequel Med Tech’s twiist™ Automated Insulin Delivery (AID) system. The integration, powered by Tidepool, is the first AID platform that can use a year‑long CGM, giving patients a single‑year sensor that eliminates frequent sensor changes while delivering real‑time glucose data.
The partnership combines Senseonics’ durable, once‑year sensor technology with Sequel’s insulin delivery system, which automatically adjusts basal insulin based on real‑time CGM readings. By pairing the Eversense 365 with the twiist pump, users can rely on continuous glucose monitoring for an entire year, reducing the daily burden of sensor replacement and simplifying diabetes management.
This launch positions Senseonics to capture a larger share of the type‑1 diabetes market, where patients and providers seek seamless, long‑term glucose monitoring coupled with automated insulin management. The integration offers a unique value proposition—an AID system that can leverage the only one‑year CGM on the market—potentially accelerating patient enrollment and expanding the company’s addressable customer base.
"As the first AID system to integrate with a year‑long CGM, twiist expands the options available to people with diabetes. People deserve choice and technology that fits the realities of their lives. Our goal is to provide a system that supports the many different ways individuals and care teams approach diabetes every day," said Joanna Mitri, M.D., M.S., Chief Medical Officer at Sequel.
"National availability of Eversense 365 with twiist marks an important next phase of our journey. It adds to the growing momentum behind Eversense 365, which is designed to provide reliable glucose data over longer periods of time to reduce the daily burden people with diabetes often face. By pairing this groundbreaking CGM with an advanced insulin delivery system, users can spend less time managing devices and more time focusing on their lives," said Brian Hansen, Chief Commercial Officer of Senseonics.
"While our technologies are unique, our goal is the same – to improve lives and reduce complexity for patients living with diabetes. We are proud to partner with Sequel and provide the necessary glucose monitoring data to power the twiist Loop algorithm, which enables real‑time insulin delivery decisions through the twiist pump. Patients and providers want reliable, long‑term automated glucose readings and we’ve taken a major step forward in simplifying and personalizing diabetes management by integrating Eversense 365’s One‑Year CGM system with the twiist AID system for patients that require insulin," said Tim Goodnow, President and CEO of Senseonics.
Senseonics has faced financial challenges, reporting a trailing‑twelve‑month revenue of $29.3 million and a 3‑year revenue growth of 3.3%. Operating and net margins are negative, at –210.54% and –217.65% respectively. The new twiist integration is expected to create a recurring revenue stream from sensor replacements and AID service fees, potentially improving the company’s profitability profile over time.
The launch is expected to accelerate patient enrollment and enhance Senseonics’ ability to scale its Eversense platform across the U.S. market, positioning the company for future growth in the type‑1 diabetes segment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.